A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol

This will be a double-blind, placebo-controlled study with a 4-way crossover design with subjects administered study drug (SJP-001), placebo, fexofenadine alone and naproxen alone on different study days, in conjunction with a quantity of alcohol estimated to be sufficient to produce a hangover the next day. The amount of alcohol may vary from subject to subject, however each subject will consume the same types and amounts of alcohol on each subsequent treatment day as consumed on the first.

NCT Number	NCT07487909
Lead Sponsor	Sen-Jam Pharmaceutical Collaborators: Cliantha Research
Conditions	Healthy
Enrollment	47 participants
Start Date	2025-09-30
Primary Completion	2025-11-21 (estimated)
Study Completion	2025-11-21 (estimated)
Updated on ClinicalTrials.gov	2026-03-23